rate, mean arterial pressure, and urinary sodium excretion and a profound increase in urine flow rate. These effects were comparable to those evoked by N/OFQ at 5 nmol. Collectively, these findings demonstrate that UFP-102 behaves as a highly potent and selective NOP receptor agonist which produces long lasting effects in vivo.
Introduction
Nociceptin /orphanin FQ (N/OFQ) (Meunier et al., 1995; Reinscheid et al., 1995) selectively activates a G-protein coupled receptor named N/OFQ peptide receptor (NOP, Cox et al., 2000) . This novel peptide / receptor system is considered "a non opioid branch of the opioid family" of peptides and receptors (Cox et al., 2000) ; this lineage is based on close structural and transductional similarities but contrasting with the pharmacological and functional differences between the N/OFQ -NOP and the classical opioid systems (Calo et al., 2000b; Mogil et al., 2001) . Via NOP receptor activation N/OFQ modulates several biological functions including pain transmission, stress and anxiety, learning and memory, locomotor activity, food intake, and the motivational properties of drugs of abuse. N/OFQ also affects the functions of peripheral systems such as the cardiovascular, gastrointestinal, renal, genitourinary and respiratory (Calo et al., 2000b; Mogil et al., 2001) .
Understanding of the roles that the N/OFQ-NOP receptor system plays in physiology and pathology is to a major extent dependent upon the identification of highly potent and selective ligands. Currently available ligands for the NOP receptor and their therapeutic potential have been recently reviewed by Zaveri (2003) ; these are i) non peptide ligands generally discovered via high throughput screening in industrial laboratories (e.g. the NOP selective antagonists J-113397 (Ozaki et al., 2000) and SB-612111 (Zaratin et al., 2004) ; ii) small peptides identified by screening of synthetic peptide combinatorial libraries (e.g. the NOP selective partial agonist Ac-RYYRWK-NH 2 (Dooley et al., 1997) or the non-selective NOP ligand peptide III-BTD (Becker et al., 1999) ); iii) N/OFQ related peptides identified by classical structure activity relationship studies (see for a review including the full agonists N/OFQ(1-13)-NH 2 and N/OFQ-NH 2 (Calo et al., 1996) , the partial agonist [Phe 1 Ψ(CH 2 -NH)Gly
In addition to these ligands, two highly potent NOP agonists have been identified by alternative strategies. In the first case, substitution of Phe 4 with (pF)Phe 4 was employed to generate [(pF)Phe 4 ]N/OFQ(1-13)-NH 2 (Bigoni et al., 2002; Rizzi et al., 2002b) . (pF)Phe is a non coded amino acid in which a hydrogen atom in the para position of the phenyl ring is substituted with the fluorine atom. In the second case, an extra pair of the basic residues, Arg and Lys, were introduced into position 14 and 15 of N/OFQ to generate [Arg 14 , Lys 15 ]N/OFQ (Okada et al., 2000) . Considering these approaches, we have combined in the N/ ] N/OFQ-NH 2 (UFP-102). In previous studies we have evaluated the pharmacological properties of UFP-101 in various in vitro and in vivo assays (Calo et al., 2002; Gavioli et al., 2003; Marti et al., 2003; McDonald et al., 2003b; Mela et al., 2004) .
In the present study we investigated the pharmacological profile of UFP-102 in vitro using cells expressing the human recombinant NOP receptor, various isolated tissues, and cerebral cortex synaptosomes which release 5-HT, and in vivo in the tail withdrawal and locomotor activity assays in mice and in cardiovascular and renal function studies performed in rats.
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7 10 -5 M) of the non-radiolabelled peptides under study. Non specific binding was defined in of 10 µM naloxone. All competition binding studies were incubated for 1 hour at room temperature and bound and free radioactivity was separated by vacuum filtration using a Brandel cell harvester using WhatmanGF/B filters soaked in polyethylenimine (0.5%) to reduce non-specific binding.
GTPγ[ 35 S] binding assay
Experimentation was performed essentially as described by Berger et al., (2000) .
Freshly prepared CHOhNOP membranes (20 µg) were incubated in 0.5 ml volumes of buffer consisting Tris (50 mM), EGTA (0.2 mM), GDP (100 µM), bacitracin (0.15 mM), BSA (1 mg/ml), peptidase inhibitors (amastatin, bestatin, captopril, phosphoramidon; 10 µM), (1 mM), forskolin (FSK) (1 µM) and varying concentrations of the peptides under study for 15 min at 37°C. Reactions were terminated by the addition of HCl (10 M) then neutralized with 10 M NaOH and 1 mM Tris, pH 7.4. The concentration of cAMP was measured using the protein binding method described by Brown et al., (1971) .
Bioassay on isolated tissues
Tissues were taken from male Swiss mice (30-35 g), albino guinea pigs (300-350 g),
and Sprague Dawley rats (300-350 g). The mouse vas deferens and colon, the guinea pig ileum, and the rat vas deferens were prepared as previously described Rizzi et al., 1999) . The mouse and rat vas deferens, and the guinea pig ileum were continuously stimulated through two platinum ring electrodes with supramaximal voltage rectangular pulses of 1 msec duration and 0.05 Hz frequency. The electrically evoked contractions (twitches) were measured isotonically with a strain gauge trasducer (Basile 7006) and recorded with the PC based acquisition system Autotrace 2.2 (RCS, Florence, Italy).
After an equilibration period of about 60 min, the contractions induced by electrical field stimulation were stable; at this time, cumulative concentration-response curves to N/OFQ or UFP-102 were performed (0.5 log-unit step) in the absence or in presence of antagonists ). These mice were genotyped by PCR. Details of the generation and breeding of mutant mice have been published previously (Nishi et al., 1997;  Neurochemical experiments on mouse cerebral cortex synaptosomes Male Swiss, CD1/C57BL6/J-129 NOP +/+ and NOP -/-mice (20-25 g) were used for these studies. On the morning of the experiment, mice were decapitated under light ether anaesthesia and the fronto-parietal cortex was isolated. Synaptosomes were prepared as previously described (Mela et al., 2004) . Briefly, the cortex was homogenized in ice-cold 0.32 M sucrose buffer at pH 7.4 then centrifuged for 10 min at 1,000 g max (4°C (Mela et al., 2004) . N/OFQ and UFP-102 were added to the superfusion medium 9 min before the K + pulse and maintained until the end of the experiment. At the end of the experiment, radioactivity retained in the superfusate samples and filters (dissolved with 1 ml of 1 M NaOH followed by 1 ml of 1 M HCl) was determined by liquid scintillation spectrophotometry using a Beckman LS 1800 β-spectrometer and Ultima Gold XR scintillation fluid (Packard Instruments B.V., Groningen, The Netherlands).
This article has not been copyedited and formatted. The final version may differ from this version. Laursen and Belknap (1986) . In brief, a 27 gauge needle attached via a polyethylene tube to a 10 µl Hamilton syringe was used for the injection at approximate 45° angle, at 2 mm lateral to the bregma midline. Each mouse only received one i.c.v. injection.
Male Sprague-Dawley rats (Harlan Inc. Indianapolis, IN) weighing 275-300 g were used for the cardiovascular and renal function studies. Rats were housed in groups of five or fewer under a 12-h light/dark cycle (light on at 7.00 AM) until the day of the experiments. All rats were fed with normal sodium diets (sodium content, 163 mEq/kg) and were allowed tap water ad libitum. All the procedures were conducted in accordance with the Louisiana State University Health Sciences Center and the National Institutes of health guidelines for the care and use of animals.
Tail-withdrawal assay
All experiments were started at 10.00 a.m. and performed according to the procedure previously described in details (Calo et al., 1998) . Briefly, the mice were placed in a holder and the distal half of the tail was immersed in water at 48 °C. Withdrawal latency time was 
Locomotor activity assay
Experiments were carried out between 14.00 and 18.00, following the procedure described by Rizzi et al. (2001a) . Briefly, the mice were routinely tested 3 min after i.c.v.
injection. Locomotor activity was assessed using Basile activity cages, which consist of a four-channel resistance detector circuit which converts the bridges "broken" by the animal paws into pulses that are summed by an electronic counter every 5 min. Total number of impulses were recorded every 5 min for 30 min. Mice were not accustomed to the cages before drug treatment and the experiment was performed in a quiet and dimly illuminated room. For each series of experiments at least 12 mice were randomly assigned to each treatment.
Cardiovascular and renal function studies
Five to six days before experimentation, rats were anesthetized with ketamine ( activity, using standard techniques previously described (Kapusta et al., 1997; Kapusta and Kenigs, 1999) . Rats were then placed in a rat holder (a chamber with Plexiglas ends connected by stainless steel rods) which permits forward and backward movement of the rat, allows for collection of urine and protects the renal nerve recording preparation. An i.v.
infusion of isotonic saline (55 ml/min) was then started and continued throughout the experiment. The experimental protocol commenced after rats regained full consciousness and cardiovascular and renal excretory function stabilized. After collection of baseline control measurements for each parameter, UFP-102 (0.055 nmol; n=6), or isotonic saline vehicle (5 µl; n=8) was injected i.c.v. Immediately after central administration, experimental urine samples (10 min consecutive periods) were collected for 90 min. Data depicted in Figure 7 for N/OFQ is from previously published studies (Kapusta et al., 1999) , and is superimposed for comparison to findings with UFP-102.
Drugs
The peptides used in this study were prepared and purified as previously described (Guerrini et al., 1997) . J-113397 was prepared as a racemic mixture, according to De Risi et al., (2001) . Captopril, amastatin, bestatin, phosphoramidon, naloxone, cAMP, 3-isobutyl-1-methylxanthine (IBMX), bovine serum albumin (BSA), guanosine 5'-O-(3-thiotri-phosphate) (GTPγS), GDP, bacitracin and forskolin (FSK) were from Sigma (Poole, UK). All tissue culture media and supplements were from Invitrogen (Paisley, U.K. In vivo data from studies in mice were analyzed as follows: raw data from tail withdrawal experiments were converted to the area under the curve (90 min); the AUC data were used for statistical analysis; locomotor activity data were analyzed statistically using the data expressed as cumulative impulses over the 30 min observation period. Cardiovascular and renal function data from rat studies were analyzed using repeated measures ANOVA.
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Bioassays in isolated tissues
In the electrically stimulated mouse and rat vas deferens and guinea pig ileum UFP-102 concentration dependently inhibited twitches eliciting maximal effects similar to N/OFQ but being 20 -48 fold more potent (table 1) (Calo et al., 1998; Reinscheid et al., 1995; Rizzi et al., 2001a) . However, whilst the N/OFQ effects appeared immediately after i.c.v. injection, those produced by UFP-102 were only evident after 30 min.
Results summarized in figure 3 show that the tail withdrawal latencies of saline injected during the 30 min experiment. Also in this assay, UFP-102 mimicked the effect of N/OFQ (Rizzi et al., 2001a) , eliciting a dose-dependent (0.01 -0.3 nmol) reduction of locomotor activity. UFP-102 was inactive at 0.01 nmol, while at 0.1 and 0.3 nmol produced a statistically significant reduction in locomotor spontaneous activity compared to salineinjected mice. 1 nmol N/OFQ produced a rapid and short lasting inhibition of spontaneous locomotor activity (Rizzi et al., 2001a) , whilst the action of the equiefficacious dose of UFP-102 (0.1 nmol) was slow in onset yet produced a long lasting inhibitory response (figure 5).
Indeed, when spontaneous locomotor activity was measured for 30 min 3h after injection, et al., 1998) behaves as a full agonist in these preparations (Mela et al., 2004; Okawa et al., 1999; Rizzi et al., 1999) whilst as a partial agonist or as an antagonist in the other preparations McDonald et al., 2003a) . Thus, in systems with large receptor reserve the difference in potency between UFP-102 and N/OFQ will tend to be underestimated.
In tissues, UFP-102 kinetics of action were slower and its effects more resistant to washout than those elicited by the natural ligand N/OFQ. Similar kinetics of action have been reported for other NOP ligands such as the peptide ZP120 (Rizzi et al., 2002a) and the non peptide Ro 64-6198 (Rizzi et al., 2001b) . The reason(s) for the differences in kinetic behaviour of these NOP agonists compared to N/OFQ are at present unknown.
Both pharmacological and knockout findings in vitro converge indicating that UFP-102 is a highly selective ligand whose effects are exclusively due to NOP receptor activation.
First, UFP-102 binds with relatively low affinity to classical opioid receptors being at least 200-fold selective for NOP; second, in functional assays the actions of UFP-102 were resistant to naloxone but inhibited by the selective NOP antagonists UFP-101 (Calo et al., 2002) and J-113397 (Bigoni et al., 2000; Ozaki et al., 2000) with pA 2 /pK B values similar to those obtained against N/OFQ; third, the effects of UFP-102 in addition to those of N/OFQ, were no longer evident in tissues (colon, vas deferens, cerebral cortex) taken from mice lacking the NOP receptor gene.
The high potency and selectivity of action of UFP-102 were confirmed in in vivo studies. UFP-102 mimicked the pronociceptive and locomotor inhibitory effects in mice and the cardiovascular and renal effects in rats produced by supraspinal administration of N/OFQ (Calo et al., 1998; Kapusta et al., 1997; Rizzi et al., 2001a) . In all these assays UFP-102 displayed higher potency than the natural peptide (between 10 and 100-fold) and produced slow onset but longer lasting effects. These kinetic features of UFP-102, also revealed by the in vitro experiments, may be attributed to a slower but stronger binding to the NOP receptor compared to N/OFQ; at least in part, they may due also to a decrease susceptibility of UFP-102 to degradation by peptidases, a feature that may be conferred to the molecule by the presence, towards the C-terminal, of the cationic residues Arg 14 ,Lys 15 (Rizzi et al., 2002c) .
The high selectivity of action of UFP-102 was also confirmed in vivo in mice. In fact, knockout studies, which represent the acid test for in vivo selectivity of action, clearly demonstrated that the biological effects of UFP-102 are solely due to NOP receptor activation. Indeed, no differences were recorded in NOP -/-mice injected with saline or UFP-102 in either the tail withdrawal or the locomotor activity assay. Cumulative impulses over the 30 min observation were used for statistical analysis. * p < 0.05 vs saline, according to ANOVA followed by the Dunnett's test. 
